Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mingyuan Li, Yuan Li, Shiqin Li, Lin Jia, Chunyang Du, Meng Li, Shuangshuang Li, Hervé Galons, Na Guo & Peng Yu. (2022) Co-delivery of F7 and crizotinib by thermosensitive liposome for breast cancer treatment. Journal of Liposome Research 32:3, pages 265-275.
Read now
Read now
Articles from other publishers (13)
I. Zerdes, C. Kamali, A. Koulouris, M. Elsayed, J. Schnorbach, P. Christopoulos & G. Tsakonas. (2023) Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases. ESMO Open 8:6, pages 102069.
Crossref
Crossref
Bole Li, Shan Liu, Honglei Feng, Chunshuang Du, Liman Wei, Jie Zhang, Guangwei Jia & Chunnuan Wu. (2023) Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib. Frontiers in Pharmacology 14.
Crossref
Crossref
Chiara Ghezzi, Stefani Perez, Kaitlin Ryan, Alicia Wong, Bao Ying Chen, Robert Damoiseaux & Peter M. Clark. (2022) Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells. Molecular Imaging and Biology 25:3, pages 541-553.
Crossref
Crossref
V. Pratap Reddy Gajulapalli, Juyong Lee & Insuk Sohn. (2023) Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors. Results in Chemistry 5, pages 100752.
Crossref
Crossref
Mohammad Jahanzeb, Huamao M Lin, Yanyu Wu, Pingkuan Zhang, Magdaliz Gorritz, Catherine B McGuiness, Wei-Ti Huang, Kainan Sun, Chi-Chang Chen & D Ross Camidge. (2022) Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. The Oncologist 27:9, pages 790-798.
Crossref
Crossref
Elite Arnon-Sheleg, Thida Win, Ora Israel, Ludmila Guralnik, Mor Moskovitz & Simona Ben-Haim. 2020. Nuclear Oncology. Nuclear Oncology
1
67
.
Elite Arnon-Sheleg, Thida Win, Ora Israel, Ludmila Guralnik, Mor Moskovitz & Simona Ben-Haim. 2020. Nuclear Oncology. Nuclear Oncology
1
67
.
Elite Arnon-Sheleg, Thida Win, Ora Israel, Ludmila Guralnik, Mor Moskovitz & Simona Ben-Haim. 2022. Nuclear Oncology. Nuclear Oncology
743
809
.
Abhay Singh, Megan M. Herr, Elizabeth A. Griffiths, Amanda Przespolewski, Mark G. Faber, Chebli Mrad, Eunice S. Wang, Theresa Hahn & Swapna Thota. (2021) Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Scientific Reports 11:1.
Crossref
Crossref
Lucy Hare, G. A. Amos Burke & Suzanne D. Turner. (2021) Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers 13:23, pages 6003.
Crossref
Crossref
Manoj MahajanNishigandha MandawadeRandeep SinghPurvish ParikhSaurabh Sharma. (2021)
6
th
Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapies
. International Journal of Molecular and Immuno Oncology 6, pages 111-117.
Crossref
Crossref
The Hong Phong Nguyen, V. Bharath Kumar, Vinoth Kumar Ponnusamy, Thi Thu Thao Mai, Phuong Tran Nhat, Kathirvel Brindhadevi & Arivalagan Pugazhendhi. (2021) Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy. Process Biochemistry 104, pages 55-75.
Crossref
Crossref
Ilaria Guerriero, Gianni Monaco, Vincenzo Coppola & Arturo Orlacchio. (2020) Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy. Pharmaceuticals 13:11, pages 413.
Crossref
Crossref